UF Health Diabetes Faculty present at IDS 2013

December 1, 2013

IDS 2013

Four distinguished UF Health diabetes experts will head ‘Down Under’ to Australia during the first week of December to highlight their Type 1 diabetes (T1D) research work at the 13th International Congress of the Immunology Diabetes Society (IDS) in Lorne, Australia.

UF Diabetes investigators Mark Atkinson PhD, Desmond Schatz M.D., Patrick Concannon PhD, and Clayton E. Matthews PhD, of the UF Health Diabetes Center of Excellence will be joined by Alberto Pugliese, M.D. of the Diabetes Research Institute in Miami, FL to present a diverse portfolio of T1D research happening throughout the state of Florida; ranging from genetic predisposition to novel combination therapy techniques.

“We are thrilled to have so many UF investigators attending,” said Mark Atkinson, PhD, Eminent Scholar for Diabetes Research and UF Preeminence Term Professorship recipient. “This event fosters collaboration among some of the brightest research investigators and institutions worldwide, and emphasizes our combined approach to ultimately finding a cure.” 

Presenters will first travel to the International Diabetes Federation (IDF) World Diabetes Conference in Melbourne Australia between December 2-6, 2013.

The Immunology of Diabetes Society is an international collaborative initiative set up to advance research related to the etiology, pathogenesis, prevention and cure of type 1 diabetes. UF Health T1D presentations will represent a combined total of over 70 years of investigative research work in the field of type 1 diabetes.

A summary of UF research presentations and abstract posters can be found below. For more information, visit www.ids2013.org

Mark Atkinson

  • nPOD Breakfast Session
  • Lessons from nPOD : Re-Writing the Textbooks on Type 1 Diabetes in Humans
  • ITN / JDRF Type 1 Diabetes Preclinical Consortium: a multi-center model for prioritizing treatment strategies in new-onset disease
  • Insulitis in type 1 diabetes
  • Short Course Oral Therapy with Plant-Derived Autoantigens Delays Type 1 Diabetes Onset in NOD Mice
  • Nardilysin-dependent proteolysis of cell-associated VTCN1(B7-H4): A novel pathway and biomarker in the development of type 1 diabetes
  • Oral delivery of Glutamic Acid Decarboxylase (GAD)-65 and IL10 by Lactococcus lactis reverses diabetes in recent-onset NOD mice

Desmond Schatz

  • ATG and GCSF, Combination Therapy for Type 1 Diabetes: Novel Mechanisms?
  • Non-HLA SNPs predicting early childhood auto-antibodies and diabetes: Teddy Study
  • Islet Antibody Remission and Risk of Type 1 diabetes in Very Young Patients in the TEDDY Study
  • The Six-year Incidence of Diabetes Associated Autoantibodies in the Genetically At-risk: The TEDDY Study

Patrick Concannon

  • Dense genotyping of autoimmune regions identifies 3 novel T1D risk loci as well as causative genes and variants at previously reported sites
  • Network analysis identifies cytokine signaling pathways involved in genetic risk common to autoimmune diseases
  • Systematic Evaluation Of Genes Associated With Type 1 Diabetes Susceptibility

Clayton Matthews

  • Impact of type 1 interferons on human beta cells